TATA-box-binding protein-associated factor 15 is a novel biomarker that promotes cell proliferation and migration in gastrointestinal stromal tumor
暂无分享,去创建一个
Chengyao Guo | Liu-ye Huang | Xu Li | Li Tang
[1] Li Tao,et al. Prognostic significance of serum CA125 in the overall management for patients with gastrointestinal stromal tumors , 2023, BMC Gastroenterology.
[2] Z. Zhao,et al. Efficacy of SCF drug conjugate targeting c-KIT in gastrointestinal stromal tumor , 2022, BMC Medicine.
[3] J. Lunec,et al. p53 as a biomarker and potential target in gastrointestinal stromal tumors , 2022, Frontiers in Oncology.
[4] Yingyong Hou,et al. Role of Surgery in the Management of Liver Metastases From Gastrointestinal Stromal Tumors , 2022, Frontiers in Oncology.
[5] Yoon-Koo Kang,et al. Clinical outcomes and prognostic factors for patients with high‐risk gastrointestinal stromal tumors treated with 3‐year adjuvant imatinib , 2022, International journal of cancer.
[6] Chuanbin Yang,et al. LncRNA MIR9-3HG enhances LIMK1 mRNA and protein levels to contribute to the carcinogenesis of lung squamous cell carcinoma via sponging miR-138-5p and recruiting TAF15. , 2022, Pathology, research and practice.
[7] Qingyuan Liu,et al. LncRNA LINC00649 recruits TAF15 and enhances MAPK6 expression to promote the development of lung squamous cell carcinoma via activating MAPK signaling pathway , 2022, Cancer Gene Therapy.
[8] Tobias Österlund,et al. FET fusion oncoproteins interact with BRD4 and SWI/SNF chromatin remodelling complex subtypes in sarcoma , 2022, Molecular oncology.
[9] Fugeng Zhang,et al. LncRNA APOA1-AS facilitates proliferation and migration and represses apoptosis of VSMCs through TAF15-mediated SMAD3 mRNA stabilization , 2021, Cell cycle.
[10] T. Triche,et al. Dysregulated heparan sulfate proteoglycan metabolism promotes Ewing sarcoma tumor growth , 2021, bioRxiv.
[11] L. Wan,et al. RAF-MEK-ERK pathway in cancer evolution and treatment. , 2021, Seminars in cancer biology.
[12] W. Peng,et al. LncRNA GAS5 activates the HIF1A/VEGF pathway by binding to TAF15 to promote wound healing in diabetic foot ulcers , 2021, Laboratory Investigation.
[13] Pilong Li,et al. Loci-specific phase separation of FET fusion oncoproteins promotes gene transcription , 2021, Nature Communications.
[14] C. Zhuang,et al. BDNF expression in GISTs predicts poor prognosis when associated with PD-L1 positive tumor-infiltrating lymphocytes , 2021, Oncoimmunology.
[15] Zongxian Zhao,et al. Novel Prognostic Nomogram for Recurrence-Free Survival of Patients With Primary Gastrointestinal Stromal Tumors After Surgical Resection: Combination of Prognostic Nutritional Index and Basic Variables , 2021, Frontiers in Oncology.
[16] E. Keung,et al. The Landmark Series: Systemic Therapy for Resectable Gastrointestinal Stromal Tumors , 2020, Annals of Surgical Oncology.
[17] D. Hallahan,et al. TAF15 contributes to the radiation-inducible stress response in cancer , 2020, Oncotarget.
[18] C. Tzen,et al. Clinical Diagnosis of Gastrointestinal Stromal Tumor (GIST): From the Molecular Genetic Point of View , 2019, Cancers.
[19] R. Yaeger,et al. Targeting Alterations in the RAF-MEK Pathway. , 2019, Cancer discovery.
[20] J. Fletcher,et al. Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours , 2019, British Journal of Cancer.
[21] Robin L. Jones,et al. Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] M. Heinrich,et al. Translational insights into gastrointestinal stromal tumor and current clinical advances , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[23] Robin L. Jones,et al. Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[24] L. Shen,et al. Chinese consensus guidelines for diagnosis and management of gastrointestinal stromal tumor , 2017, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.
[25] S. Nishizuka,et al. α-Amanitin Restrains Cancer Relapse from Drug-Tolerant Cell Subpopulations via TAF15 , 2016, Scientific Reports.
[26] J. Jónasson,et al. KIT and PDGFRA mutations and the risk of GI stromal tumor recurrence. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] L. Tora,et al. TAF15 is important for cellular proliferation and regulates the expression of a subset of cell cycle genes through miRNAs , 2013, Oncogene.
[28] J. Lasota,et al. Gastrointestinal stromal tumors. , 2013, Gastroenterology clinics of North America.
[29] J. Blay,et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial , 2013, The Lancet.
[30] A. Guialis,et al. Domains involved in TAF15 subcellular localisation: dependence on cell type and ongoing transcription. , 2012, Gene.
[31] Aki Vehtari,et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. , 2012, The Lancet. Oncology.
[32] H. Vollmers,et al. Diagnostic and therapeutic potential of a human antibody cloned from a cancer patient that binds to a tumor-specific variant of transcription factor TAF15. , 2010, Cancer research.
[33] A. Ståhlberg,et al. The multifunctional FUS, EWS and TAF15 proto-oncoproteins show cell type-specific expression patterns and involvement in cell spreading and stress response , 2008, BMC Cell Biology.
[34] T. Glisovic,et al. RNA‐binding proteins and post‐transcriptional gene regulation , 2008, FEBS letters.
[35] H. Gehring,et al. Identification and characterization of the nuclear localization/retention signal in the EWS proto-oncoprotein. , 2006, Journal of molecular biology.
[36] G. Hicks,et al. TLS, EWS and TAF15: a model for transcriptional integration of gene expression. , 2006, Briefings in functional genomics & proteomics.
[37] S. L. Wong,et al. Towards a proteome-scale map of the human protein–protein interaction network , 2005, Nature.
[38] S. Nunobe,et al. Surgery including liver resection for metastatic gastrointestinal stromal tumors or gastrointestinal leiomyosarcomas. , 2005, Japanese journal of clinical oncology.
[39] M. Mann,et al. RNA and RNA Binding Proteins Participate in Early Stages of Cell Spreading through Spreading Initiation Centers , 2004, Cell.
[40] Samuel Singer,et al. PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors , 2003, Science.
[41] L. Sobin,et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. , 2002, Human pathology.
[42] J. Lasota,et al. Gastrointestinal stromal tumors: recent advances in understanding of their biology. , 1999, Human pathology.
[43] D. Immanuel,et al. TLS (FUS) binds RNA in vivo and engages in nucleo-cytoplasmic shuttling. , 1997, Journal of cell science.